Vor Biopharma (VOR) Net Equity Issued and Repurchased (2020 - 2025)
Vor Biopharma (VOR) posted quarterly Net Equity Issued and Repurchased of $49.8 million for Q4 2025, up 226686.36% year-over-year from N/an in Q4 2024, and up 146.08% quarter-over-quarter from $20.3 million in Q3 2025.
Vor Biopharma (VOR) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Vor Biopharma (VOR) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $49.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased rose 226686.36% year-over-year to $49.8 million; the TTM figure through Dec 2025 stood at $70.1 million (up 25393.09% YoY), while the FY2025 annual figure was $70.1 million, up 25393.09% from the prior year.
- Net Equity Issued and Repurchased rose to $49.8 million in Q4 2025 per VOR's latest filing, from $20.3 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $49.8 million in Q4 2025 and bottomed at -$92000.0 in Q2 2024.
- Historically, Net Equity Issued and Repurchased has averaged $9.6 million across 5 years, with a median of $392000.0 in 2023.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased tumbled 115.89% — and 2025, when it surged 226686.36%.
- Vor Biopharma's Net Equity Issued and Repurchased stood at $45.4 million in 2021, then plunged by 99.77% to $106000.0 in 2022, then plunged by 114.15% to -$15000.0 in 2023, then tumbled by 46.67% to -$22000.0 in 2024, then soared by 226686.36% to $49.8 million in 2025.
- Business Quant data shows VOR's Net Equity Issued and Repurchased at $49.8 million in Q4 2025, $20.3 million in Q3 2025, and -$22000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.85 Mn |
| Dec 31, 2025 | 49.85 Mn |
| Sep 30, 2025 | 20.26 Mn |
| Sep 30, 2025 | 20.26 Mn |
| Dec 31, 2024 | -22,000.00 |
| Dec 31, 2024 | -22,000.00 |
| Sep 30, 2024 | 111,000.00 |
| Sep 30, 2024 | 111,000.00 |
| Jun 30, 2024 | -92,000.00 |
| Jun 30, 2024 | -92,000.00 |
| Mar 31, 2024 | 278,000.00 |
| Mar 31, 2024 | 278,000.00 |
| Dec 31, 2023 | -15,000.00 |
| Dec 31, 2023 | -15,000.00 |
| Sep 30, 2023 | 392,000.00 |
| Sep 30, 2023 | 392,000.00 |
| Jun 30, 2023 | 579,000.00 |
| Jun 30, 2023 | 579,000.00 |
| Mar 31, 2023 | 3.62 Mn |
| Mar 31, 2023 | 3.62 Mn |